CellOnco™ HEK293T-Tg(Human B2 Receptor) Division-Arrested Cell, Single Clone (CAT#: ITS-0624-HMM524)

Creative Biolabs offers HEK293T-Tg(Human B2 Receptor) Division-Arrested Cell which B2 receptor stably expressed in HEK293T cells.

HEK293T-Tg(Human B2 Receptor) Division-Arrested Cell was engineered to express the receptor human B2 (NM_000623). This cell line can be used to study B2 receptor function, signaling pathways, and potential therapeutic interventions. Dividing-arrest cells are cells that are normally kept under specific culture conditions or treated with agents that prevent cell division from being held in a non-dividing state. This can be achieved through methods such as serum starvation, chemical inhibitors of cell cycle progression, or genetic modification.

Well-characterized stable cell lines;
for cell-based high-throughput screening;
Low-cost evaluation of stable cell lines or limited quantities of compounds.

B2 receptor function, signaling pathways, and potential therapeutic interventions.

GPCR

B2

Bradykinin

Human

HEK293T

Full-length Human BDKRB2 cDNA (GenBank Accession Number NM_000623) with FLAG-tag sequence at the N-terminus

NM_000623

Bradykinin receptor B2 is a G protein-coupled receptor for bradykinin. B2 receptor agonists may have important clinical value in the treatment and prevention of various cardiovascular disorders such as hypertension, ischemic heart disease, left ventricular hypertrophy, ventricular remodeling and congestive heart failure, as well as diabetic disorders by mimicking the reported beneficial effects of bradykinin. Blocking bradykinin B2 receptors after experimental cerebral ischemia reduces brain edema, infarct volume and neuronal necrosis, and improves neurological outcome. Thus, B2 antagonists may be a promising new class of compounds for clinical use after the onset of cerebral ischemia.